AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06051006 — intervention group
Intervention type: OTHER
Intervention: Device setting
Description: The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1).
Study NCT06051006 — intervention group
Intervention type: OTHER
Intervention: Speech audiometry
Description: This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1).
Study NCT06051006 — intervention group
Intervention type: OTHER
Intervention: Intelligibility in noise test
Description: The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1).
Study NCT06051006 — intervention group
Intervention type: OTHER
Intervention: Cochlear implant datalogging, speech audiometry test, FraSimat test
Description: The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR.
Study NCT05065450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Stimulation
Description: Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
Study NCT06368934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sub-lobectomy
Description: Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
Study NCT06368934 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: imaging total resection
Description: Imaging total resection (T1-enhanced borders) will met the RANO criteria
Study NCT02742311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic disectomy
Description: Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
Study NCT05283187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy Group
Description: Mindfulness Based Cognitive Therapy
Study NCT05664802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Description: A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
Study NCT05664802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Description: A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
Study NCT05329870 — intervention group
Intervention type: OTHER
Intervention: SNP array
Description: SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
Study NCT05954429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serplulimab
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10
Study NCT05954429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
Study NCT05375214 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)
Description: Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
Study NCT05095857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine
Description: S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
Study NCT05095857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline (placebo)
Description: Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
Study NCT05675228 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Knowledge about genital herpes
Study NCT04611763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil preoperatively
Description: give Flurbiprofen axetil 15 min before surgery
Study NCT04611763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen axetil postoperatively
Description: give Flurbiprofen axetil at the end of surgery
Study NCT00013169 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Strong Patient Focus
Study NCT05580068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertension therapy through iATROS medical device
Description: The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better.
Study NCT04882787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTE hearing aid
Description: Amplification
Study NCT06033872 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Focused education, medication adjustment and telemonitoring
Description: 1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software.
Study NCT06134479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
Description: On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Study NCT06134479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
Description: On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Study NCT04982276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK109
Description: Subjects will receive AK109 by intravenous administration.
Study NCT04982276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Subjects will receive AK109 in combination with paclitaxel.
Study NCT04826016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study NCT04826016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study NCT04624906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg oral capsules twice daily for 1 year
Study NCT04982276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Subjects will receive AK104 and AK109 in combination with paclitaxel.
Study NCT04982276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.
Study NCT01295073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trientine Hydrochloride
Description: Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery.
Study NCT01295073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
Description: see above
Study NCT04826016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study NCT04624906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 on days 1 and 2 of each cycle.
Study NCT04624906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
Study NCT05606796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: 1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
Study NCT06221085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Pressure Threshold (PPT)
Description: Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure.
Study NCT06296602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.
Description: A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
Study NCT05751850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Description: HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
Study NCT05751850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel; gemcitabine
Description: nab-paclitaxel in combination with gemcitabine
Study NCT05561192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises
Description: The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
Study NCT05561192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory and strength exercise
Description: During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity.
Study NCT05561192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooperative sports activities group
Description: Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills.
Study NCT05561192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical education class
Description: The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
Study NCT06148805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises
Study NCT06148805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises
Study NCT05040360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05040360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04777292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of a mobile health application until app completion
Description: Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
Study NCT04777292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a mobile health application until app completion
Description: Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
Study NCT06191107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable Partial Denture
Description: Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
Study NCT05755802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered.
Study NCT05755802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder block
Description: The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
Study NCT05899582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracranial-Intracranial Bypass Surgery
Description: Extracranial-intracranial bypass surgery plus medical treatment
Study NCT05899582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment alone
Description: Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.